|
1
|
Walker CL and Stewart EA: Uterine
fibroids: the elephant in the room. Science. 308:1589–1592.
2005.
|
|
2
|
Wegienka G: Are uterine leiomyoma a
consequence of a chronically inflammatory immune system? Med
Hypotheses. 79:226–231. 2012.
|
|
3
|
Ciarmela P, Islam MS, Reis FM, et al:
Growth factors and myometrium: biological effects in uterine
fibroid and possible clinical implications. Hum Reprod Update.
17:772–790. 2011.
|
|
4
|
Räsänen K and Vaheri A: Activation of
fibroblasts in cancer stroma. Exp Cell Res. 316:2713–2722.
2010.
|
|
5
|
Hanahan D and Coussens LM: Accessories to
the crime: functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012.
|
|
6
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011.
|
|
7
|
Kunz-Schughart LA and Knuechel R:
Tumor-associated fibroblasts (part I): Active stromal participants
in tumor development and progression? Histol Histopathol.
17:599–621. 2002.
|
|
8
|
Kunz-Schughart LA and Knuechel R:
Tumor-associated fibroblasts (part II): Functional impact on tumor
tissue. Histol Histopathol. 17:623–637. 2002.
|
|
9
|
Moore AB, Yu L, Swartz CD, et al: Human
uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma
cell proliferation and collagen type I production, and activate
RTKs and TGF beta receptor signaling in coculture. Cell Commun
Signal. 8:102010.
|
|
10
|
Stewart EA, Friedman AJ, Peck K and Nowak
RA: Relative overexpression of collagen type I and collagen type
III messenger ribonucleic acids by uterine leiomyomas during the
proliferative phase of the menstrual cycle. J Clin Endocrinol
Metab. 79:900–906. 1994.
|
|
11
|
Stewart EA: Uterine fibroids. Lancet.
357:293–298. 2001.
|
|
12
|
Flake GP, Andersen J and Dixon D: Etiology
and pathogenesis of uterine leiomyomas. Environ Health Perspect.
111:1037–1054. 2003.
|
|
13
|
Mladenović-Mihailović A,
Mladenović-Bogdanović Z, Mitrović P, et al: Immunocytochemical
characteristics of submucosal uterine myomas. Vojnosanit Pregl.
67:977–982. 2010.(In Serbian).
|
|
14
|
Sugimoto H, Mundel TM, Kieran MW and
Kalluri R: Identification of fibroblast heterogeneity in the tumor
microenvironment. Cancer Biol Ther. 5:1640–1646. 2006.
|
|
15
|
Border WA and Ruoslahti E: Transforming
growth factor-beta in disease: the dark side of tissue repair. J
Clin Invest. 90:1–7. 1992.
|
|
16
|
Feghali CA and Wright TM: Cytokines in
acute and chronic inflammation. Front Biosci. 1:12–26. 1997.
|
|
17
|
Gentle ME, Shi S, Daehn I, et al:
Epithelial cell TGFβ signaling induces acute tubular injury and
interstitial inflammation. J Am Soc Nephrol. 24:787–799. 2013.
|
|
18
|
Powell DW, Mifflin RC, Valentich JD, Crowe
SE, Saada JI and West AB: Myofibroblasts. II. Intestinal
subepithelial myofibroblasts. Am J Physiol. 277:C183–C201.
1999.
|
|
19
|
Powell DW, Mifflin RC, Valentich JD, et
al: Myofibroblasts. I Paracrine cells important in health and
disease. Am J Physiol. 277:C1–C9. 1999.
|
|
20
|
Sarkar A, Donkor MK and Li MO: T cell- but
not tumor cell-produced TGF-β1 promotes the development of
spontaneous mammary cancer. Oncotarget. 2:1339–1351. 2011.
|
|
21
|
Colotta F, Allavena P, Sica A, et al:
Cancer-related inflammation, the seventh hallmark of cancer: links
to genetic instability. Carcinogenesis. 30:1073–1081. 2009.
|
|
22
|
Witherspoon JT and Butler VW: The etiology
of uterine fibroids with special reference to the frequency of
their occurrence in the Negro: a hypothesis. Surg Gynecol Obstet.
58:57–61. 1934.
|
|
23
|
Laughlin SK, Schroeder JC and Baird DD:
New directions in the epidemiology of uterine fibroids. Semin
Reprod Med. 28:204–217. 2010.
|
|
24
|
Grande MT and López-Novoa JM: Fibroblast
activation and myofibroblast generation in obstructive nephropathy.
Nat Rev Nephrol. 5:319–328. 2009.
|
|
25
|
Buscemi L, Ramonet D, Klingberg F, et al:
The single-molecule mechanics of the latent TGF-β1 complex. Curr
Biol. 21:2046–2054. 2011.
|
|
26
|
Le Goff C and Cormier-Daire V: From tall
to short: the role of TGFβ signaling in growth and its disorders.
Am J Med Genet C Semin Med Genet. 160C:145–153. 2012.
|
|
27
|
Wang W, Koka V and Lan HY: Transforming
growth factor-beta and Smad signalling in kidney diseases.
Nephrology (Carlton). 10:48–56. 2005.
|
|
28
|
Wang C, Chen L, Wang L and Wu J: Crystal
structure of the MH2 domain of Drosophila Mad. Sci China C Life
Sci. 52:539–544. 2009.
|
|
29
|
Petersen A, Joly P, Bergmann C, Korus G
and Duda GN: The impact of substrate stiffness and mechanical
loading on fibroblast-induced scaffold remodeling. Tissue Eng Part
A. 18:1804–1817. 2012.
|
|
30
|
Ingber DE: From cellular
mechanotransduction to biologically inspired engineering: 2009
Pritzker Award Lecture, BMES Annual Meeting October 10, 2009. Ann
Biomed Eng. 38:1148–1161. 2010.
|
|
31
|
Ingber DE: Cellular tensegrity: defining
new rules of biological design that govern the cytoskeleton. J Cell
Sci. 104:613–627. 1993.
|
|
32
|
Legant WR, Miller JS, Blakely BL, et al:
Measurement of mechanical tractions exerted by cells in
three-dimensional matrices. Nat Methods. 7:969–971. 2010.
|
|
33
|
Sarasa-Renedo A and Chiquet M: Mechanical
signals regulating extracellular matrix gene expression in
fibroblasts. Scand J Med Sci Sports. 15:223–230. 2005.
|
|
34
|
Carmeliet G, Vico L and Bouillon R: Space
flight: a challenge for normal bone homeostasis. Crit Rev Eukaryot
Gene Expr. 11:131–144. 2001.
|
|
35
|
Rogers R, Norian J, Malik M, et al:
Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet
Gynecol. 198:e1–e11. 2008.
|
|
36
|
Malik M, Segars J and Catherino WH:
Integrin β1 regulates leiomyoma cytoskeletal integrity and growth.
Matrix Biol. 31:389–397. 2012.
|
|
37
|
Gurtner GC, Dauskardt RH, Wong VW, et al:
Improving cutaneous scar formation by controlling the mechanical
environment: large animal and phase I studies. Ann Surg.
254:217–225. 2011.
|
|
38
|
Hinz B: Masters and servants of the force:
the role of matrix adhesions in myofibroblast force perception and
transmission. Eur J Cell Biol. 85:175–181. 2006.
|
|
39
|
Prager-Khoutorsky M, Lichtenstein A,
Krishnan R, et al: Fibroblast polarization is a
matrix-rigidity-dependent process controlled by focal adhesion
mechanosensing. Nat Cell Biol. 13:1457–1465. 2011.
|
|
40
|
Eckes B, Nischt R and Krieg T: Cell-matrix
interactions in dermal repair and scarring. Fibrogenesis Tissue
Repair. 3:42010.
|
|
41
|
Walker RG, Willingham AT and Zuker CS:
A Drosophila mechanosensory transduction channel. Science.
287:2229–2234. 2000.
|
|
42
|
Sadoshima J and Izumo S: The cellular and
molecular response of cardiac myocytes to mechanical stress. Annu
Rev Physiol. 59:551–571. 1997.
|
|
43
|
Shi-Wen X, Thompson K, Khan K, et al:
Focal adhesion kinase and reactive oxygen species contribute to the
persistent fibrotic phenotype of lesional scleroderma fibroblasts.
Rheumatology. 51:2146–2154. 2012.
|
|
44
|
Nakayama K, Obara K, Tanabe Y, et al:
Interactive role of tyrosine kinase protein kinase C, and Rho/Rho
kinase systems in the mechanotransduction of vascular smooth
muscles. Biorheology. 40:307–314. 2003.
|
|
45
|
Kawaguchi M, Takahashi M, Hata T, Kashima
Y, Usui F, Morimoto H, Izawa A, Takahashi Y, Masumoto J, Koyama J,
et al: Inflammasome activation of cardiac fibroblasts is essential
for myocardial ischemia/reperfusion injury. Circulation.
123:594–604. 2011.
|
|
46
|
Martinez-Outschoorn UE, Trimmer C, Lin Z,
Whitaker-Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S,
Martinez-Cantarin MP, Capozza F, et al: Autophagy in cancer
associated fibroblasts promotes tumor cell survival: Role of
hypoxia, HIF1 induction and NFκB activation in the tumor stromal
microenvironment. Cell Cycle. 9:3515–3533. 2010.
|
|
47
|
Burke DL, Frid MG, Kunrath CL, Karoor V,
Anwar A, Wagner BD, Strassheim D and Stenmark KR: Sustained hypoxia
promotes the development of a pulmonary artery-specific chronic
inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol.
297:L238–L250. 2009.
|
|
48
|
Stenmark KR, Gerasimovskaya E, Nemenoff RA
and Das M: Hypoxic activation of adventitial fibroblasts: role in
vascular remodeling. Chest. 122(Suppl 6): S326–S334. 2002.
|
|
49
|
Gerasimovskaya EV, Ahmad S, White CW,
Jones PL, et al: Extracellular ATP is an autocrine/paracrine
regulator of hypoxia-induced adventitial fibroblast growth.
Signaling through extracellular signal-regulated kinase-1/2 and the
Egr-1 transcription factor. J Biol Chem. 277:44638–44650. 2002.
|
|
50
|
Short M, Nemenoff RA, Zawada WM, et al:
Hypoxia induces differentiation of pulmonary artery adventitial
fibroblasts into myofibroblasts. Am J Physiol Cell Physiol.
286:C416–C425. 2004.
|
|
51
|
Wright JL: Diseases of the small airways.
Lung. 179:375–396. 2001.
|
|
52
|
Spivak-Kroizman TR, Hostetter G, Posner R,
et al: Hypoxia triggers hedgehog-mediated tumor-stromal
interactions in pancreatic cancer. Cancer Res. 73:3235–3247.
2013.
|
|
53
|
Haskó G, Csóka B, Németh ZH, et al: A(2B)
adenosine receptors in immunity and inflammation. Trends Immunol.
30:263–270. 2009.
|
|
54
|
Zhong H, Belardinelli L, Maa T and Zeng D:
Synergy between A2B adenosine receptors and hypoxia in activating
human lung fibroblasts. Am J Respir Cell Mol Biol. 32:2–8.
2005.
|
|
55
|
Pilch H, Schlenger K, Steiner E, et al:
Hypoxia-stimulated expression of angiogenic growth factors in
cervical cancer cells and cervical cancer-derived fibroblasts. Int
J Gynecol Cancer. 11:137–142. 2001.
|
|
56
|
Wu MP, Young MJ, Tzeng CC, et al: A novel
role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma
reaction by inhibiting activated fibroblasts from invading cancer.
Carcinogenesis. 29:1115–1123. 2008.
|
|
57
|
Bertin N, Clezardin P, Kubiak R and
Frappart L: Thrombospondin-1 and -2 messenger RNA expression in
normal, benign, and neoplastic human breast tissues: correlation
with prognostic factors, tumor angiogenesis, and fibroblastic
desmoplasia. Cancer Res. 57:396–399. 1997.
|
|
58
|
Wu MP, Tzeng CC, Wu LW, Huang KF and Chou
CY: Thrombospondin-1 acts as a fence to inhibit angiogenesis that
occurs during cervical carcinogenesis. Cancer J. 10:27–32.
2004.
|
|
59
|
Kalas W, Yu JL, Milsom C, et al: Oncogenes
and Angiogenesis: down-regulation of thrombospondin-1 in normal
fibroblasts exposed to factors from cancer cells harboring mutant
ras. Cancer Res. 65:8878–8886. 2005.
|
|
60
|
Kuhn C and Mason RJ: Immunolocalization of
SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J
Pathol. 147:1759–1769. 1995.
|
|
61
|
Heinemann V, Reni M, Ychou M, et al:
Tumour-stroma interactions in pancreatic ductal adenocarcinoma:
rationale and current evidence for new therapeutic strategies.
Cancer Treat Rev. 40:118–128. 2014.
|
|
62
|
Chlenski A, Guerrero LJ, Yang Q, Tian Y,
Peddinti R, Salwen HR and Cohn SL: SPARC enhances tumor stroma
formation and prevents fibroblast activation. Oncogene.
26:4513–4522. 2007.
|
|
63
|
Mettouchi A, Cabon F, Montreau N, et al:
SPARC and thrombospondin genes are repressed by the c-jun oncogene
in rat embryo fibroblasts. EMBO J. 13:5668–5678. 1994.
|
|
64
|
Sangaletti S, Stoppacciaro A, Guiducci C,
et al: Leukocyte, rather than tumor-produced SPARC, determines
stroma and collagen type IV deposition in mammary carcinoma. J Exp
Med. 198:1475–1485. 2003.
|
|
65
|
Bhoopathi P, Gondi CS, Gujrati M, et al:
SPARC mediates Src-induced disruption of actin cytoskeleton via
inactivation of small GTPases Rho-Rac-Cdc42. Cell Signal.
23:1978–1987. 2011.
|
